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Abstract 
 
Marine organisms and their metabolites are a diverse source of scaffolds for potential pharmacological 
molecular probes and, less frequently, for pharmaceutical lead compounds. In this study, 157 synthetic 
analogues of marine sponge-derived alkaloids clathrodin and oroidin were screened against replicon 
models of two RNA viruses, hepatitis C (HCV) and Chikungunya virus (CHIKV) as part of a larger 
screening project. Four compounds were found to selectively inhibit the HCV replicon (IC50 1.6-4.6 
µM). These belong to the 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole class of compounds originally 
designed to target the ATP-binding site of bacterial DNA gyrase. The ATP-binding site of this bacterial 
protein has high structural similarity to the ATP-binding site of heat shock protein 90 (Hsp90), a host-
cell chaperone universally required for viral replication, which led us to examine inhibition of Hsp90 as 
the compounds’ potential mechanism of action. Binding of the four hit compounds to Hsp90 was 
evaluated through microscale thermophoresis and molecular modelling, which supported our 
hypothesis of interaction with Hsp90 (Kd 18-79 µM) as basis for the compounds’ antiviral activity. The 
presented novel structural class of small molecules that target the Hsp90 ATP-binding site has excellent 
potential for further antiviral drug development because of the compounds’ low toxicity and synthetic 
accessibility. 
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1. Introduction 
 
Marine sponges are a rich source of natural products possessing a variety of biological activities.[1] The 
chemical versatility of sponges has provided numerous developmental pharmaceuticals.[2] Due to 
challenges in collection and cultivation of marine sponge species, chemical synthesis extends the 
possibilities to study the bioactive properties of sponge-derived compounds and their derivatives. 
Clathrodin and oroidin are pyrrole-2-aminoimidazole alkaloids isolated from sponges of the genus 
Agelas, and were initially shown to display voltage-gated sodium channel modulatory activity[3] and 
inhibition of bacterial biofilm formation[4], respectively. Recently, we have designed and synthesized 
several structural series of conformationally restricted oroidin analogues and reported their biological 
activities including voltage-gated sodium channel modulatory activity[5-8], inhibition of bacterial biofilm 
formation[9], induction of apoptosis in THP-1 and HepG2 cell lines[10], DNA gyrase inhibition[11-12]  and 
antimicrobial activity[13]. 
 
This study encompassed the biological evaluation of 157 synthetic clathrodin and oroidin analogues for 
their antiviral activity. All compounds were initially screened in replicon models of two RNA viruses, 
Hepatitis C virus (HCV; genus Hepacivirus) and Chikungunya virus (CHIKV; genus Alphavirus). 
HCV is a small, enveloped, positive-stranded (+)-RNA virus that causes severe liver disease, a global 
public health problem estimated to cause 500 000 deaths annually.[14] HCV therapy relied for long on 
the use of interferons together with the guanosine analogue ribavirin. In recent years, introduction of 
direct-acting antivirals has brought notable progress to the clinical treatment of HCV infections.[15] 
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Despite recent therapeutic advances, the treatment costs are extremely high and novel therapies are 
therefore out of reach for most HCV patients even in high-income countries.[16] Chikungunya virus is 
spread by Aedes mosquitoes and it is the cause of Chikungunya fever.[17] This disease causes acute high 
fever, polyarthralgia, myalgia, nausea, headache and skin symptoms, as well as relapsing chronic 
rheumatic manifestations. There are currently no specific treatments or vaccines against CHIKV.  
 
The aim of the primary evaluation of the compound library was finding compounds with potential to 
suppress viral replication. The use of replicon cell models enables identification of potential 
suppressors of viral replication in an efficient manner and without the need for biosafety level 3 (BSL-
3) handling. Using models of two different RNA-viruses in the first study phase made it possible to 
identify compounds that target non-viral proteins involved in the replication cycle in addition to 
compounds that have selectivity between the models. Based on the primary evaluation in the HCV and 
CHIKV models, four hit compounds 1-4, all of which belong to the 4,5,6,7-tetrahydrobenzo[1,2-
d]thiazole structural class of oroidin analogues, were selected and subjected to further evaluation. The 
objectives of these follow-up studies were to determine the compounds’ efficacy, specificity and 
antiviral mechanism of action.  
 
2. Methods and materials 
 
2.1. Design of 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole structural class of oroidin analogues 
Since marine alkaloids clathrodin, hymenidin and oroidin (Fig. 1) possess a potentially unstable double 
bond between the pyrrolamide and 2-aminoimidazole moieties[18], we designed and synthesized several 
libraries of their conformationally restricted analogues.[10] Among them we prepared a library of 
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4,5,6,7-tetrahydrobenzo[1,2-d]thiazol-2-amine derivatives in which the imidazole ring was isosterically 
replaced by the thiazole ring (Fig. 1, class I; Supplementary table S1, compounds 2, 5-11).[6] Recently, 
compounds 2 and 11 (Fig. 1 and Supplementary table S1) were identified as Escherichia coli DNA 
gyrase inhibitors and were subjected to structure-based optimization which resulted in potent DNA 
gyrase inhibition (Fig. 1, class II; Supplementary table SI, compounds 1, 3, 4, 12-38).[11] The above 
mentioned screening library of 157 oroidin analogues contained 38 compounds of this structural type.  
  
Fig. 1. Design of conformationally restricted oroidin analogues and their optimization toward potent 
DNA gyrase inhibitors. 
 
2.2. Screening of compounds in Chikungunya virus (CHIKV) and hepatitis C virus (HCV) replicon 
cells 
A library of 157 synthetic analogues based on the lead structures of marine alkaloids clathrodin and 
oroidin was subjected to primary screening in both HCV and CHIKV replicon cell models. In the 
primary screening phase, all compounds were tested in triplicate at a concentration of 50 µM. The 
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activity threshold in the primary screening phase was set at >50% inhibition of replicon expression for 
both applied models.  
 
 
 
2.3. Cell culture 
The Huh-7 cell line expressing a HCV replicon was kindly provided by Prof. Ralf Bartenschlager 
(University of Heidelberg, DE) and has been described by Vrojlik and co-workers (2003).[19] Under 
continuous G418 selection, the cell line expresses a subgenomic replicon of the HCV genotype 1b 
genome and a firefly luciferase marker, which enables sensitive detection of replicon suppression. The 
HCV replicon cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% 
fetal bovine serum, 100 IU/mL penicillin, 100 µg/mL streptomycin, 292 µg/mL L-glutamine, 1% non-
essential amino acids and 250 µg/mL G418. Cells were maintained aseptically in incubators with a 5% 
CO2 atmosphere at 37 °C and were routinely passaged (2-3 times a week). The maximum passage 
number for cells used in the experiments was 30. The cells were tested for mycoplasma and found to be 
free of mycoplasma contamination. 
 
The baby hamster kidney (BHK-21) cell line carrying a CHIKV replicon (BHK-CHIKV-NCT) was 
kindly provided by Prof. Andres Merits (University of Tartu, EE) and used as a model to study CHIKV 
replication inhibition similarly as in Pohjala et al. (2011) and Lillsunde et al. (2014).[20-21]  
 
2.4. Evaluation of viral replicon suppression in primary screen
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The HCV replicon assay was optimized and validated by dose-response experiments for the positive 
control, ribavirin (Sigma-Aldrich Co., Saint Louis, MO, US), which in the 24-hour experiments had an 
average IC50 value of 110 μM. In primary screening of the compound library, inhibition of the HCV 
replicon was evaluated after 24 h exposure to compounds. The HCV replicon cells were seeded onto 
opaque-white and clear-bottomed 96-well microplates (PerkinElmer Inc., Waltham, MA, US) at a 
density of 30 000 cells/well. The plates were incubated at 37 °C overnight. Compounds were dissolved 
in DMSO and before addition to plates diluted using assay medium composed of Dulbecco’s modified 
Eagle’s medium supplemented with 5% fetal bovine serum, 100 IU/mL penicillin, 100 µg/mL 
streptomycin, 292 µg/mL L-glutamine, and 1% non-essential amino acids. After 24 hours, the replicon 
inhibition was evaluated by measuring luciferase expression by using a Luciferase Assay System kit 
(Promega Co., Madison, WI, US) according to the manufacturer’s instructions. A Varioskan Flash plate 
reader (Thermo Fisher Scientific, FI) was used for the luminescence measurements.  
 
The CHIKV assay was carried out as previously described in Pohjala et al. (2011) and Lillsunde et al. 
(2014).[20-21] The positive control, 6-azauridine (Sigma-Aldrich Co., Saint Louis, MO, US) had an 
average IC50 of 2 μM.  
 
2.5. Evaluation of effects on cell viability  
In order to eliminate possible false positives, the hit compounds from the primary replicon screens were 
tested for host cell cytotoxicity in both replicon-carrying cell lines. Test conditions were identical to 
those of the primary anti-replicon assays. After exposure to the compounds, cell viability was 
determined by ATP quantitation using a CellTiter GLO® Luminescent Cell Viability Assay Kit 
(Promega Co., Madison, WI, US). The luminescent signal was recorded using a Varioskan Flash plate 
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reader (Thermo Fisher Scientific, FI). The cytotoxic agent polymyxin B (Sigma-Aldrich Co., Saint 
Louis, MO, US) was used as positive control on each assay plate and for assay validation in the 
cytotoxicity assays for both cell lines. Polymyxin B had a CC50 value of 5900 IU/mL in the CHIKV 
replicon cells (48-h exposure) and 7900 IU/mL in the HCV replicon cells (24-h exposure). 
 
2.6. Dose-response experiments 
Further experiments were performed for confirmed hits from the preliminary screen to evaluate dose-
response with regard to both replicon inhibition as well as host cell toxicity. Dose-response 
experiments were carried out according to the same protocol as the primary screening, except that a 48-
h incubation period was applied also for HCV replicon cells. The assay time was extended from the 
original 24-h incubation in the HCV model, in order to better detect potential toxic effects and obtain 
results comparable to the 48-h assay in CHIKV replicon cells. A minimum of three independent dose-
response experiments with three replicates for each concentration were performed for each compound. 
Logarithmic concentration ranges were applied to all dose-response experiments and concentrations 
were selected to cover the full range of compound activity. A second positive control, the characterized 
Hsp90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) (InvivoGen, 
San Diego, CA, US) was included in the dose-response experiments in order to enable comparison of 
test compounds to a known Hsp90 inhibitor. In HCV replicon cells, 17-DMAG had an IC50 value of 
0.06 µM and a CC50 value of 1.7 µM [selectivity index (SI) 28]. In CHIKV replicon cells, the IC50 
value of 17-DMAG was 0.04 µM and the CC50 value 0.14 µM (SI 4). 
 
2.7. Data analysis and assay quality 
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The percentage of inhibition of the viral replicons was calculated by comparing the sample signal to the 
yielded maximum signal (DMSO vehicle in assay medium). The cytotoxic effect was calculated as a 
percentage by using the maximum signal (DMSO-treated cells) as the reference and wells with reagent 
only as the background value. For dose-response data, IC50 and CC50 values were calculated by fitting 
the dose-response data to sigmoidal dose-response curves using OriginPro 8.6 software (OriginLab, 
Northampton, MA, US). All IC50 and CC50 values are given as the average ± standard deviation of three 
independent experiments. Selectivity indices (SI) were calculated by dividing the CC50 value with the 
IC50 value. Assay quality was monitored throughout experiments by calculating the signal-to-
background ratio (S/B), signal-to-noise ratio (S/N) and Z’-factor for the plates.[22] 
 
2.8. Molecular modelling  
Three-dimensional models of compounds 1-4 were built in ChemBio3D Ultra 13.0 (GAMESS 
interface, ChemBio3D Ultra 13.0, ChemBioOffice Ultra 13.0, CambridgeSoft, Cambridge, MA, US). 
Their geometries were optimized using MMFF94 force field and partial atomic charges were added.[23] 
Energy was minimized until the gradient value was smaller than 0.001 kcal/(mol Å). The optimized 
structure was further refined with GAMESS interface in ChemBio3D Ultra 13.0 using the 
semiempirical AM1 method, QA optimization algorithm and Gasteiger Hückel charges for all atoms 
for 100 steps (GAMESS interface, ChemBio3D Ultra 13.0, ChemBioOffice Ultra 13.0, CambridgeSoft, 
Cambridge, MA, US). Molecular docking calculations were performed using FlexX [24-25],  as available 
in Lead IT (version 2.1.3., BioSolve IT GmbH, DE), running on four octal core AMD Opteron CPU 
processors, 16 GB RAM, two 750 GB hard drives, running 64-bit Scientific Linux 6.0. The receptor 
was prepared in a LeadIT graphical user interface using the Receptor wizard. Amino acid residues 
within a radius of 6.5 Å around the ligand from the X-ray structure of the human Hsp90β (PDB entry: 
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3NMQ[26]) were defined as the binding site. Hydrogen atoms were added to the binding site residues 
and correct tautomers and protonation states were assigned. Water molecules, except HOH242, and the 
ligand were deleted from the crystal structure.  
 
The FlexX molecular docking program, as available in LeadIT (version 2.1.3., BioSolve IT GmbH, 
DE), was used for ligand docking. A hybrid algorithm (enthalpy and entropy driven ligand binding) 
was used to place the ‘base fragment’. The maximum number of solutions per iteration and the 
maximum number of solutions per fragmentation parameter values were increased to 1000, while other 
parameters were set at their default values. Proposed binding modes and scoring function scores of the 
top ten highest scored docking poses per ligand were evaluated and the highest ranked binding pose 
was used for graphical representation in PyMOL (Delano Scientific LLC, San Francisco, CA, US). 
 
2.9. Hsp90 binding studies by microscale thermophoresis 
The compounds that exhibited dose-dependent inhibition in the HCV replicon screen were studied 
using microscale thermophoresis (MST) to assess binding to Hsp90. Human heat shock protein 90β 
(GenBank Accession No. AY359878), full length with C-terminal His tag, MW = 83 kDa, expressed in 
an E. coli expression system, was purchased from Sigma-Aldrich Co. (Saint Louis, MO, US). The 
protein was labelled with red fluorescent dye NT-647-NHS, by using the Monolith NT™ Protein 
Labeling Kit RED – NHS (NanoTemper Technologies GmbH, München, DE) according to the 
manufacturer’s instructions. Compounds were dissolved in ethanol and a dilution series of the 
compounds (16 concentrations, 0.003 to 100 µM) and the control 17-DMAG (14 concentrations, 
0.0015 to 12.5 µM) were prepared using the MST buffer (50 mM Tris-HCl pH 7.4 with 150 mM NaCl, 
10 mM MgCl2 and 0.05% Tween-20). The buffer additionally contained 5% (v/v) ethanol. The test 
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compounds in buffer were carefully mixed with labelled Hsp90 (final concentration 35 nM) and 
transferred into Monolith NT.115 premium-coated capillaries (NanoTemper Technologies GmbH, 
München, DE). Measurements were performed in a NanoTemper Monolith NT.115 instrument 
(NanoTemper Technologies GmbH, München, DE) using 20% LED power and 20% MST power. 
Three independent measurements were performed for each compound. Results were analyzed and the 
dissociation constant Kd ± standard deviation calculated based on the thermophoresis and temperature 
jump data from three individual experiments by using the NT Analysis software (NanoTemper 
Technologies GmbH, München, DE). 
 
 
 
 
3. Results  
3.1.Primary screening and hit selection 
In primary screening of the library of 157 clathrodin and oroidin analogues, 30 compounds showed 
over 50% inhibition of the HCV replicon (hit rate 19%) and 15 compounds inhibited the CHIKV 
replicon by more than 50% (hit rate 9.6%). The full primary data for the 4,5,6,7-tetrahydrobenzo[1,2-
d]thiazole structural class of oroidin analogues (1-38) can be found in Supplementary table S1. Most of 
the primary hits were excluded based on results from the confirmatory follow-up studies due to host 
cell toxicity (Supplementary table S1), lack of efficacy or insufficient dose-response correlation in the 
follow-up studies. As a result of hit evaluation, four compounds (1-4, Fig. 2) were found to show 
potent inhibition of the HCV replicon at low micromolar concentrations (IC50 value range 1.6-4.6 µM).  
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Fig. 2. Structures of compounds 1-4 and 17-DMAG, the characterized Hsp90 inhibitor used as positive 
control in the study. 
 
The compounds’ target selectivity was evaluated by comparing the IC50 values to corresponding CC50 
values (50% cytotoxicity). The dose-response curves from anti-replicon assays and cytotoxicity 
experiments in HCV replicon cells are shown in Supplementary figure F1. With selectivity indices 
ranging from 22 up to 61 (Table 1), the compounds were shown to possess excellent selectivity. 
Compounds 1-4 were consequently chosen for further evaluation in order to elucidate their mechanism 
of action.  
 
Table 1. Biological activity of compounds 1-4 and the reference compounds 17-DMAG and ribavirin 
determined in the HCV replicon system and by microscale thermophoresis. Results of the HCV 
replicon assay (time of exposure 48 h) are average ± s.d. from three independent dose-response 
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experiments with three replicates for each concentration. Dissociation constants (Kd) of the control 
compound 17-DMAG, compounds 1-4 and human Hsp90 were determined by microscale 
thermophoresis and are expressed as average ± s.d. of three independent experiments.  
 
 
Compound 
IC
50 
HCV replicon 
(µM)  
CC
50
 
HCV replicon 
(µM) 
 
Selectivity index 
 
Kd Hsp90 
(µM) 
1  4.6 ± 0.43 101 ± 7.9 22 19 ± 5.7 
2  1.6 ± 0.08 98 ± 8.7 61 39 ± 14 
3  3.1 ± 0.8 84 ± 1.8 27 79 ± 17 
4  2.8 ± 0.35 78 ± 4.0 28 18 ± 3.4 
17-DMAG 0.06 ± 0.01 1.7±0.25 28 0.27 ± 0.02 
Ribavirin 64±7.0 > 300 ND ND 
3.2. Molecular target and selectivity 
A common structural feature of compounds 1-4 is the unsubstituted 2-amino group on a 4,5,6,7-
tetrahydrobenzo[1,2-d]thiazole skeleton and a hydrophobic, substituted pyrrolamide or indolamide 
moiety. In contrast, compounds with unsubstituted pyrrolamide or indolamide moiety and/or 
substituted 2-amino group were found to be less potent or inactive. As the active compounds 1-4 had 
been initially found to bind to the ATP-binding site of bacterial DNA gyrase,[11] we speculated that 
binding to the structurally related ATP-binding pocket of the cellular chaperone Hsp90 might be the 
mechanism causing the observed virus replicon suppression.   
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To assess the assumed mechanism of action, the water-soluble Hsp90 inhibitor 17-
dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) was evaluated in the HCV 
replicon cell model as an additional reference compound. Indeed, 17-DMAG very efficiently 
suppressed the HCV replicon (IC50 = 0.06 µM) whereas the suppression by compounds 1-4 was ca. 25- 
to 75-times weaker (Table 1). The impact of Hsp90 suppression on HCV in replicon cells and 
humanized liver mice has previously been shown by Nakagawa et al.(2007).[27] However, 17-DMAG is 
cytotoxic at low concentrations (CC50 = 1.7 µM), with a selectivity index of 28. Out of hit compounds 
1-4, the highest selectivity was observed for compound 2 (SI 61), which had 2-fold higher selectivity 
than the positive control 17-DMAG. The compounds data was also compared to ribavirin, the antiviral 
agent that has traditionally been used in clinical HCV treatment. The inhibitory effect of ribavirin in the 
HCV replicon model is very modest (IC50 64 µM) compared to compounds 1-4 and 17-DMAG (Table 
1).   
 
The compounds identified as potential CHIKV inhibitors in the primary screen exhibited moderate 
selectivity and efficacy against the CHIKV replicon in dose-response and cytotoxicity studies 
(Supplementary table S1). Amongst the selected four hit compounds, compound 2 showed replicon 
suppression in both HCV and CHIKV models. Compound 2 inhibited the CHIKV replicon with an IC50 
value of 42 µM and its cytotoxicity CC50 value was 81 µM, and it thus possessed limited selectivity and 
potency. Interestingly, also the control compound 17-DMAG has restricted anti-replicon selectivity in 
the CHIKV cell model (IC50 = 0.04 µM; CC50 = 0.14 µM; SI 4).  
 
3.3. Investigation of the binding mode to Hsp90 by molecular docking 
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Bacterial DNA gyrase and human Hsp90 belong to the GHKL (gyrase, Hsp90, histidine kinase and 
DNA mismatch repair protein MutL) ATPase/kinase superfamily and share the unconventional 
Bergerat ATP-binding fold.[28] This led to suggesting Hsp90 as the possible target of the ATP-
competitive DNA gyrase inhibitors 1-4. Furthermore, the co-crystal structure of E. coli DNA gyrase in 
complex with a pyrrolamide inhibitor shows a similar hydrogen bonding network between the 
pyrrolamide moiety and Asp73,[12] which is also predicted by molecular docking of compounds 1-4 in 
the DNA gyrase ATP-binding site[11]. Therefore, plausible binding modes of compounds 1-4 in the 
ATP-binding site of human Hsp90 were studied by molecular docking experiments. Pyrrolamide 
moieties of 1 and 2 and indolamide moieties of 3 and 4 mimic the binding of the adenine ring of ATP 
by forming hydrogen bonds with Asp93 and Thr184 side chains and a conserved water molecule (Fig. 
3). An additional hydrogen bond between Asp102 side chain and amino group of aminothiazole of 1-4 
is predicted (Fig. 3). Since similar binding modes and scoring function scores of compounds 1-4 were 
predicted, the observed differences in experimental Kd values cannot be rationalized based on docking 
results. 
 
a)             b) 
  
Fig. 3. Docking binding mode of compound a) 2 (in cyan sticks) and b) 3 (in magenta sticks) in the 
ATP-binding site of human Hsp90β (PDB entry: 3NMQ; in green). Amino acid residues Asp93, 
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Asp102 and Thr184, which are involved in formation of hydrogen bonds (black dashed lines) with the 
ligand are presented as yellow sticks. 	
 
3.4. Evaluation of binding to Hsp90 by microscale thermophoresis (MST) 
In order to assess our hypothesis of Hsp90 as the molecular target and confirm the observations from 
Hsp90 docking studies, we evaluated the binding of compounds 1-4 to Hsp90 by microscale 
thermophoresis (MST), which allows determination of binding affinities based on movement of the 
particles on a microscopic temperature gradient.[29] Because expression of the β-isoform of Hsp90 is 
upregulated in HCV-infected cells, we chose to use Hsp90β in the MST experiments.[30] As in the cell-
based replicon assays, the known Hsp90 inhibitor 17-DMAG was used as positive control in MST. The 
Kd obtained in our experiment for 17-DMAG was 0.27 ± 0.02µM, which corresponds well to the 
dissociation constant 0.35 ± 0.04 µM previously reported for wild-type Hsp90 by Onuoha et al. 
(2007).[31]  
The strongest interaction with Hsp90 was observed for compound 4, which had a Kd of 18 ± 3.4 µM 
(Table 1). However, the assay setup in the MST experiments allowed testing at maximum 100 µM 
concentration, and thus the results should be considered as a primary finding. 
 
4. Discussion 
 
The similarities of ATP-binding sites of DNA gyrase and Hsp90 provides a coherent explanation to 
why some compounds designed to bind to the ATP-binding site of bacterial DNA gyrase also interact 
with Hsp90. Our results are in line with previous findings, where inhibition of Hsp90 has been 
discovered to be an efficient pathway of interfering with virus replication. In literature, a few former 
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studies of Hsp90 inhibitors with anti-HCV activity have been reported.[32-34] These previous findings 
focused on geldanamycin and its derivatives. Although these geldanamycin derivatives were shown to 
be very potent Hsp90 inhibitors as well as antiviral agents, compounds 1-4 described in our study 
represent not only a new structural class of potential Hsp90 inhibitors, but are also small in size, 
synthetically easily accessible and offer great prospects for further optimization towards more potent 
compounds.  
 
All of the four most promising compounds 1-4 identified in the replicon screens showed binding to 
Hsp90 in the MST experiment but there was, however, no clear correlation between the IC50 values in 
the HCV replicon assay and the binding to Hsp90 (Table 1). The compounds’ IC50 values differ little 
from each other whilst there are clearer differences in cytotoxicity towards the HCV replicon host cells 
and Hsp90 binding. The lack of correlation between HCV replicon IC50 and binding to Hsp90 might be 
explained by several factors. The solvent in the cell-based assays was DMSO, whereas ethanol was the 
most suitable solvent for MST experiments. Even though the compounds were soluble in both DMSO 
and ethanol at the highest used concentrations, it is possible that differences in solubility behavior have 
affected the results. At this phase the possibility of other targets in addition to Hsp90 can also not be 
excluded.  
 
The cellular functions and targets of Hsp90 are numerous. Hsp90-type proteins are encountered in 
virtually all cell compartments in eukaryotic cells, and they are one of the most abundant protein types 
found in cytoplasm.[35] Hsp90 is needed both under normal physiological conditions and under 
conditions of cellular stress, such as elevated temperature.[36] Hsp90 gains energy from binding and 
hydrolyzing ATP to assist conformational changes of more than 20 co-chaperones. Hydrolyzing ATP 
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causes a change in the conformation of Hsp90, which induces conformational changes in the client 
protein. The first identified functions of Hsp90 were facilitation of the maturation of protein kinases 
and steroid hormone receptors.[37-38] Other identified clients of Hsp90 are proteins involved in 
transcription, translation, mitochondrial function, kinetochore assembly, centrosome and cell cycle 
function.[36] Hsp90 targets also include proteins involved in regulation of secretory pathway functions 
and membrane trafficking.  
 
Considering the important role of Hsp90 in regulation of the cellular functions and cell proliferation, it 
is not surprising that Hsp90 has been studied extensively as a target protein for cancer treatment. Hsp90 
enables proper protein stability and folding in cancer cells, which makes tumor cells hypersensitive to 
Hsp90 inhibition.[39] Small molecules targeted to bind to Hsp90 are capable of disturbing the activity of 
receptors, kinases and transcription factors involved in oncogenesis. More strikingly, however, also 
viruses are almost universally dependent on Hsp90.[36] In our study, the replicon-inhibiting activity was 
mostly specific for either CHIKV or HCV – only compound 2 possessed activity against both the HCV 
and CHIKV replicons. Hsp90 has been shown to play several important roles in the HCV replication 
cycle. It mediates the maturation of non-structural protein 2/3, ensures the proper folding of HCV 
replication proteins and regulates phosphorylation of non-structural protein 5A; all of which are crucial 
functions for successful HCV propagation.[40] Based on current literature, the effects of Hsp90 in the 
viral replication cycle are better characterized for HCV than they are for alphaviruses such as CHIKV.  
 
Rapid evolution of viruses causes complications when developing directly acting antivirals that target 
viral proteins, and it makes antiviral drug discovery as well as treatment of patients challenging from 
both medical and economic perspectives. On the contrary, targeting host factors as a strategy in 
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antiviral drug development offers the possibility to obtain effects against a broader spectrum of viral 
pathogens, with a reduced likelihood for development of resistance. The major concern related to 
inhibition of a host protein is naturally unwanted side effects arising from disturbance of the normal 
cellular functions. However, viral replication has been shown to be sensitive to Hsp90 inhibitors at 
concentrations that do not affect cellular viability.[36] In accordance with the literature,[36] compounds 1-
4 caused toxicity only at high concentrations in the cell models, and the observed specificity indicates 
that doses effective in inhibition of replication functions are far below those that cause relevant 
toxicity. It is notable that the affinity of compounds 1-4 to Hsp90 is not as strong as that of the positive 
control 17-DMAG, which still leaves room for structural optimization in order to improve binding. 
 
5. Conclusions 
In conclusion, the promising inhibitory effect of compounds 1-4 in the HCV replicon system led us to 
investigate Hsp90 as a target behind their effects on the replication of viral RNA. Preliminary binding 
studies by microscale thermophoresis demonstrated binding of 1-4 to Hsp90 and highlighted these 
compounds as a potential novel structural class of Hsp90 inhibitors. The HCV replicon suppression 
was exhibited by these compounds at low micromolar concentrations, and most importantly, at 
concentrations that have no negative effects on cell viability. Questions that remain to be answered are 
whether the effects seen in replicon models can be replicated using full virus assays and other more 
advanced models. Furthermore, it remains to be determined whether the 4,5,6,7-tetrahydrobenzo[1,2-
d]thiazole class of oroidin analogues are capable of inhibiting the replication of other viruses. Because 
of their excellent synthetic accessibility, these compounds nevertheless offer great potential for further 
optimization of their binding affinity to Hsp90. Inhibition of host factors such as Hsp90 may be an 
advantageous therapeutic strategy for treatment of viral infections in the future. 
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